Oncocount RGCC Test
Oncocount RGCC Test
What are Identified ?
Test Results
Test Type
Test Frequency
Sample Required
Blood sample
Cancer Type
All type of CancersBlood Sample Qty
15 ml peripheral whole blood
Sample Test Report
DESCRIPTION
ONCOCOUNT TEST RGCC, as the name suggests it gives the count of Circulating Tumour Cells (CTC’s) present in blood.
Oncocount RGCC detects the presence of Circulating Tumour Cells (CTC’s) and measures their concentration in the blood. As these CTCs could lead to the recurrence of cancer, this test is useful to detect an early relapse, and as a follow-up tool.
RESEARCH ARTICLES
- Flow Cytometric Detection of Circulating Tumor Cells in Breast Cancer Patients: A Blinded Study.
- A Novel Method for Colorectal Cancer Screening Based on Circulating Tumor Cells and Machine Learning.
- Recent Advances in Methods for Circulating Tumor Cell Detection.
- Clinical associations of mucin 1 in human lung cancer and precancerous lesions
- Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma.
- CD63 expression in metastatic melanoma and melanocytic nevi in lymph nodes.
- Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine.
- Tracking cancer progression: from circulating tumor cells to metastasis.
- Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther.
Pre Test Counseling is given to the patient inorder to determine if CTC test is correct.
CTCs can be used to determine improved therapy monitoring.
CTCs can be used as a diagnostic and prognostic factor for cancer therapy.
CTCs can be used in classification of cancer patients based on risk scale.
CTCs can evaluate patient response to therapy.
CTCs can evaluate treatment efficacy.
CTCs can predict disease progression.
CTCs can be used to adjust therapeutic dosage.
Evaluates patient status post therapy.
Evaluates complete response.
Evaluates Maintenance therapy.